Medical and Health News - MediPaper Medical Communications Ltd.

ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

30th June 2020

ASCO 2020 Lung, Breast, and Liver Cancer Update

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

5th June 2020

US FDA approved immune-checkpoint inhibitors updated 05-Jun-2020

Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

30th April 2020

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

19th February 2020

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

11th February 2020

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

24th January 2020

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

12th January 2020

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

12th June 2019

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

3rd June 2019

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

24th April 2019

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

22nd April 2019

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

Immunoncology I-O drugs and immunotherapy for renal cancer RCC

5th March 2019

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

16th January 2019

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

5th December 2018

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

4th December 2018

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

3rd July 2020

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia

26th February 2020

Updated: Clinical characteristics of patients with COVID-19

Dr Siddharth Sridhar - 2019-nCoV COVID-19 in Hong Kong - the end of the beginning

22nd February 2020

COVID-19 in Hong Kong: the end of the beginning?

Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港，人們如何感染Covid-19

20th February 2020

How do people get COVID-19 in Hong Kong

Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

7th February 2020

2019-nCoV – Summary of the situation in HK as of Feb 6, 2020

Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

3rd February 2020

How infectious is novel coronavirus (2019-nCoV)

Dr Siddharth Sridhar - How stable are coronaviruses in the environment? 2019-nCoV 冠狀病毒在環境中的穩定性 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2nd February 2020

2019-nCoV: how stable are coronaviruses in the environment?

Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia

1st February 2020

Who gets severe novel coronavirus (2019-nCoV) infection?

Somazina citicoline small vessel disease vascular cognitive impairment traumatic brain injury neuroimaging cerebrovascular disorders ischaemic haemorraghic stroke rehabilitation neuroprotection

16th December 2019

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

26th April 2019

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

CANCERINFORMER

腫瘤學新知 Cancer Informer 癌症資訊癌症治療癌症腫瘤確診患癌究竟甚麼是癌癌症怎樣醫

MediPaper Medical Communications Ltd

BREAKING

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia WARS Wuhan Pneumonia coronavirus outbreak sars mers COVID-19 2019-nCoV WuhanOutbreak Pneumonia

MediPaper Medical Communications Ltd

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

CONFERENCE HIGHLIGHTS

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ECTRIMS2018 multiple sclerosis MS neurology

©ECTRIMS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

Therapeutic Areas

Therapeutic Areas

ONCOLOGY ARTICLES

ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

30th June 2020

ASCO 2020 Lung, Breast, and Liver Cancer Update

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

5th June 2020

US FDA approved immune-checkpoint inhibitors updated 05-Jun-2020

Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

30th April 2020

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

19th February 2020

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

11th February 2020

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

cancer informer 腫瘤學新知分享腫瘤領域最新進展包含熱議話題、專題和實用工具例如 NCCN ASCO 及 ESMO 消息更新

MediPaper Medical Communications Ltd

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia WARS Wuhan Pneumonia coronavirus outbreak sars mers COVID-19 2019-nCoV WuhanOutbreak Pneumonia

MediPaper Medical Communications Ltd

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

ONCOLOGY ARTICLES (Cont’d)

Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

22nd November 2018

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

Transarterial radioembolisation (TARE) is historically used as a treatment option for intermediate to advanced stage hepatocellular carcinoma (HCC) who are not a candidate for transarterial chemoembolisation (TACE), evidence supports an emerging role for TARE in unresectable HCC at an early stage.

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

21st November 2018

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

3rd November 2018

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

31st October 2018

Management of Immune-Mediated Hepatitis: a Case Report

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

15th October 2018

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11th October 2018

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Pembrolizumab plus chemotherapy effective in squamous NSCLC

8th October 2018

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

7th October 2018

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

5th October 2018

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

5th October 2018

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

ESMO-2018-ESMO18-pembrolizumab-nivolumab-durvalumab-atezolizumab-avelumab-ipilimumab-tremelimumab-osimertinib-cabozantinib-lenvatinib-lorlatinib

©European Society for Medical Oncology

ECTRIMS2018 multiple sclerosis MS neurology

©ECTRIMS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

ERAS guidelines for antenatal and preoperative care in caesarean delivery 1

21st January 2019

ERAS guidelines for antenatal and preoperative care in caesarean delivery

The Enhanced Recovery after Surgery (ERAS) Society recently published Part 1 of the Society's 3-part caesarean delivery guidelines, focussed on pre-operative care for women undergoing scheduled and unscheduled caesarean delivery, in the American Journal of Obstetrics & Gynecology. Caesarean delivery is the most common surgical procedure in the modern world.

Dr Paul Kessler - Euroanaesthesia 2018 - Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

©Aspen Pharmacare

26th December 2018

Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

Dr Ngai LIU - Euroanaesthesia 2018 - Closed-Loop or Automated Titration of IV Anaesthesia Impact on Routine Anaesthesia

©Aspen Pharmacare

25th December 2018

Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

3rd December 2018

Efficacy of oral Cladribine for MS durable after a two-year treatment course

Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

27th November 2018

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

©MediPaper Medical Communications Ltd

22nd November 2018

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

18th November 2018

I-O in Special Populations: Chronic Viral Hepatitis Carriers

Early treatment with ocrelizumab lowers 5-year brain atrophy-rates in MS

25th October 2018

Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

28th September 2018

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

TAVR vs SAVR - Transcatheter- vs surgical aortic valve replacement in high-risk patients 5-years survival

28th September 2018

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

MediPaper Medical Communications Agency Hong Kong Blog

MediPaper Medical Communications Agency Hong Kong Blog